ָ ת	֚֚֚֚֚֚֝֝֝֝֝֝֝֝֝֜֜֝֝֜֜֝֝֜֜֜֜֝֜֜֜֜֝֓֜֜֝֓֡֜֜֜֝֡֡֜֜֜֝֓֡֓֜֜֝֡֡֡֜֜֡֡֡
Ü	
Y	֡
M	\ \ \ \ \
E	>
Ĭ	7
٤	?
77.1	
•	•

International Apple JP 2063/6/605
Application filed by: 20 months onths
WIPO PUBLICATION INFORMATION:
Publication No.: WO JOSE 133 Publication Language: English German Japanese Chinese Korem
Not Published: Q U.S. only designated Q EP months
THE ANAL APPLICATION PAPERS IN THE APPLICATION FILE:
International Application (RECORD COPY) PCT/IB/331
Article 19 Amendments
PCT/IPEA/409 IPER: Q EP Q JP Q SE Q AU Q PCT/ISA DIA CONTRA
OUS OFR OCH OES ORU OAT OKR O OUS OFR OCH OES ORU OAT OKR O
D PCT/IPEA/409 IPER was NOT AVAILABLE at the time of paperlegat review D HONE
Annexes to 409
Priority Document (s) No Other: 26%
Utalet
RECEIPTS FROM THE APPLICANT (other than checked above): Basic National Fee (or authorization to charge) Preliminary Amendment(s) Filed on a
Preliminary Amendment(s) Filed on :
Description Claims Claims Abstract 198 M Information Disclaration Claims
Description La Claims La Abstract Miscommation Disclosure Statement(s) Filed on:
Drawing Figure Assignment Document (forwards)
Assignee PG Publication Notice
Substitute Specification Filed on:
O replaced by Article 34 Amendment
Annexes to 409 Verified Small Status Statement
Oath/ Declaration (executed)
Q so translation Q other:
Application Data Sheet DNA Diskette Sequence Listing
Power of Attorney/ Change of Address
NOTES:
S U.S.C. 371 - Receipt of Request (PTO-1390) ONNON MACLISING SOLVER
Date Acceptable Oath/ Declaration Received Problems Problems Designation Received
Pate of Completion of requirements under 35 U.S.C. 371
ate of Completion of ALL requirements
ate of Completion of BO/EO 903 - Notification of Acceptance
ate of Completion of DO/ EO 905 - Notification of Missing Requirements
ate of Completion of DO/ EO 909 - Notification of Abandonment
ate of Completion of DO/ EO 916 - Notification of Defective Response
ate of Completion of DO/EO 922 - Notification to Comply w/ Requirements for Patent
pplications Containing Nucleotide and/or Amino Acid Sequence Disclosures ate of Completion of DO/EO 923
or complement in DO/ EU 723